Last reviewed · How we verify
IV interferon
At a glance
| Generic name | IV interferon |
|---|---|
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- flu like symptoms
- Asthenia
- INFLUENZA LIKE ILLNESS
- Anaemia
- Constipation
- Nausea
- Decreased appetite
- Diarrhoea
- INJECTION SITE ERYTHEMA
- HEADACHE
- Injection site erythema
- Influenza like illness
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (PHASE3)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma (PHASE1)
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial (PHASE2)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV interferon CI brief — competitive landscape report
- IV interferon updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI